Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.

A series of beta-sulfonyl hydroxamate TACE inhibitors, bearing a butynylamino or a butynyloxy P1' group, was designed and synthesized. Of the compounds investigated, 22 has excellent potency against isolated TACE enzyme, shows good selectivity over MMP-2 and MMP-13, and oral activity in an in vivo mouse model of TNF-alpha production.

[1]  Shin-Ichiro Nishimura,et al.  Synthesis and biological activity of selective azasugar-based TACE inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[2]  P. Rutgeerts,et al.  Anti-TNF agents in Crohn’s disease , 2000, Expert opinion on investigational drugs.

[3]  Jeremy Levin,et al.  Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[4]  J. Kneer,et al.  (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase. , 2002, The Journal of pharmacology and experimental therapeutics.

[5]  A. Cope,et al.  Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis. , 1992, Progress in growth factor research.

[6]  R. Black,et al.  Identification and Characterization of 4-[[4-(2-Butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a Novel Dual Tumor Necrosis Factor-α-Converting Enzyme/Matrix Metalloprotease Inhibitor for the Treatment of Rheumatoid Arthritis , 2004, Journal of Pharmacology and Experimental Therapeutics.

[7]  P. Reinemer,et al.  The metzincins — Topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a super family of zinc‐peptidases , 1995, Protein science : a publication of the Protein Society.

[8]  R. Magolda,et al.  Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). , 2003, Bioorganic & medicinal chemistry letters.

[9]  J. Peterson.  Matrix Metalloproteinase Inhibitor Development and the Remodeling of Drug Discovery , 2004, Heart Failure Reviews.

[10]  R. Huber,et al.  Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Feldmann,et al.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.

[12]  E. Kaldjian,et al.  Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. , 2003, Arthritis and rheumatism.

[13]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[14]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[15]  J. Skotnicki,et al.  Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates. , 2005, Bioorganic & medicinal chemistry letters.

[16]  S. Nishimura,et al.  Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents. , 2004, Journal of medicinal chemistry.

[17]  C. Walker,et al.  Pharmacological profile of PKF242‐484 and PKF241‐466, novel dual inhibitors of TNF‐α converting enzyme and matrix metalloproteinases, in models of airway inflammation , 2002, British journal of pharmacology.

[18]  M. Feldmann,et al.  Localization of tumour necrosis factor‐alpha (TNF‐α) and its receptors in normal and psoriatic skin: epidermal cells express the 55‐kD but not the 75‐kD TNF receptor , 1993, Clinical and experimental immunology.

[19]  Chen Lihua,et al.  Discovery of γ-Lactam Hydroxamic Acids as Selective Inhibitors of Tumor Necrosis Factor α Converting Enzyme: Design, Synthesis, and Structure−Activity Relationships , 2002 .

[20]  J. Levin,et al.  Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[21]  N. Hooper,et al.  Families of zinc metalloproteases , 1994, FEBS letters.